159 related articles for article (PubMed ID: 35341683)
1. Cost-effectiveness analysis of infliximab for the treatment of Kawasaki disease refractory to the initial treatment: A retrospective cohort study.
Takura T; Horiuchi S
J Cardiol; 2022 Aug; 80(2):172-178. PubMed ID: 35341683
[TBL] [Abstract][Full Text] [Related]
2. Plasma exchange and infliximab as a third-line therapy for refractory infantile Kawasaki disease.
Ansai H; Masuda H; Nakao H; Nishimura N; Kubota M
Pediatr Int; 2022 Jan; 64(1):e15226. PubMed ID: 35831245
[TBL] [Abstract][Full Text] [Related]
3. [Retrospective analysis of infliximab in the treatment of Kawasaki disease].
Xie LP; Zhao L; Chu C; He L; Liang XC; Sun SN; Zhao QM; Wang F; Cao YY; Lin YX; Zeng ZQ; Wu L; Huang GY; Liu F
Zhonghua Er Ke Za Zhi; 2022 Jan; 60(1):14-19. PubMed ID: 34986617
[No Abstract] [Full Text] [Related]
4. Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review.
Crayne CB; Mitchell C; Beukelman T
Pediatr Rheumatol Online J; 2019 Nov; 17(1):77. PubMed ID: 31775898
[TBL] [Abstract][Full Text] [Related]
5. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
[TBL] [Abstract][Full Text] [Related]
6. Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients.
Hachiya A; Kobayashi N; Matsuzaki S; Takeuchi Y; Akazawa Y; Shigemura T; Motoki N; Masumoto J; Agematsu K
Clin Rheumatol; 2018 Jul; 37(7):1937-1943. PubMed ID: 29302828
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
Lei WT; Chang LS; Zeng BY; Tu YK; Uehara R; Matsuoka YJ; Su KP; Lee PC; Cavalcante JL; Stubbs B; Lin PY; Wu YC; Hsu CW; Chen TY; Chen YW; Yeh PY; Sun CK; Tseng PT; Kao YH
EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339
[TBL] [Abstract][Full Text] [Related]
8. Infliximab is the new kid on the block in Kawasaki disease: a single-centre study over 8 years from North India.
Singh S; Sharma D; Suri D; Gupta A; Rawat A; Rohit MK
Clin Exp Rheumatol; 2016; 34(3 Suppl 97):S134-8. PubMed ID: 27086575
[TBL] [Abstract][Full Text] [Related]
9. Infliximab for the Treatment of Refractory Kawasaki Disease: A Nationwide Survey in Japan.
Masuda H; Kobayashi T; Hachiya A; Nakashima Y; Shimizu H; Nozawa T; Ogihara Y; Ito S; Takatsuki S; Katsumata N; Suzuki Y; Takenaka S; Hirono K; Kobayashi T; Suzuki H; Suganuma E; Takahashi K; Saji T;
J Pediatr; 2018 Apr; 195():115-120.e3. PubMed ID: 29224935
[TBL] [Abstract][Full Text] [Related]
10. Effective infliximab therapy for the early regression of coronary artery aneurysm in Kawasaki disease.
Nagatomo Y; Muneuchi J; Nakashima Y; Nanishi E; Shirozu H; Watanabe M; Uike K; Nagata H; Hirata Y; Yamamura K; Takahashi Y; Okada S; Suzuki Y; Hasegawa S; Ohga S
Int J Cardiol; 2018 Nov; 271():317-321. PubMed ID: 30144998
[TBL] [Abstract][Full Text] [Related]
11. Current knowledge of TNF-α monoclonal antibody infliximab in treating Kawasaki disease: a comprehensive review.
Chen J; Liao J; Xiang L; Zhang S; Yan Y
Front Immunol; 2023; 14():1237670. PubMed ID: 37936712
[TBL] [Abstract][Full Text] [Related]
12. Kawasaki disease: a comprehensive review of treatment options.
Patel RM; Shulman ST
J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis.
Wang L; He M; Wang W; Li S; Zhao G
Eur J Pediatr; 2024 Apr; 183(4):1765-1776. PubMed ID: 38240765
[TBL] [Abstract][Full Text] [Related]
14. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
Burns JC; Roberts SC; Tremoulet AH; He F; Printz BF; Ashouri N; Jain SS; Michalik DE; Sharma K; Truong DT; Wood JB; Kim KK; Jain S;
Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057
[TBL] [Abstract][Full Text] [Related]
15. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
Li X; Tang Y; Ding Y; Chen Y; Hou M; Sun L; Qian G; Qin L; Lv H
Eur J Pharmacol; 2021 May; 899():173985. PubMed ID: 33652059
[TBL] [Abstract][Full Text] [Related]
16. Infliximab regulates monocytes and regulatory T cells in Kawasaki disease.
Koizumi K; Hoshiai M; Katsumata N; Toda T; Kise H; Hasebe Y; Kono Y; Sunaga Y; Yoshizawa M; Watanabe A; Kagami K; Abe M; Sugita K
Pediatr Int; 2018 Sep; 60(9):796-802. PubMed ID: 29543362
[TBL] [Abstract][Full Text] [Related]
17. Infliximab plus plasma exchange rescue therapy in Kawasaki disease.
Sonoda K; Mori M; Hokosaki T; Yokota S
J Pediatr; 2014 May; 164(5):1128-1132.e1. PubMed ID: 24560183
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional regulation by infliximab therapy in Kawasaki disease patients with immunoglobulin resistance.
Ogihara Y; Ogata S; Nomoto K; Ebato T; Sato K; Kokubo K; Kobayashi H; Ishii M
Pediatr Res; 2014 Sep; 76(3):287-93. PubMed ID: 24964229
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness of infliximab for Kawasaki disease in children: systematic review and meta-analysis.
Li D; Li X; Dou W; Zheng Y
Transl Pediatr; 2021 May; 10(5):1294-1306. PubMed ID: 34189087
[TBL] [Abstract][Full Text] [Related]
20. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.
Chan H; Chi H; You H; Wang M; Zhang G; Yang H; Li Q
BMC Pediatr; 2019 May; 19(1):158. PubMed ID: 31101091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
